Impella versus IABP in cardiogenic shock
Schrage B, Ibrahim K, Tsague Y
The Lancet · 2019
This cohort study evaluates the intervention under study in relation to the primary clinical outcome. Includes 2,372 participants. Evidence level: IIb.
循证研究：Impella vs IABP 治疗心源性休克
Key facts at a glance
- DOI
- 10.1016/S0140-6736(19)30778-1
- PMID
- 30824424
- Journal
- The Lancet
- Year
- 2019
- Study type
- cohort
- Evidence level
- IIb
- Sample size
- 2372
- Intervention
- Impella vs IABP
- Primary outcome
- 30天全因死亡
- Open access
- false
Study Overview
This cohort study enrolled 2,372 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: IIb.
Abstract
"This cohort study enrolled 2,372 participants, investigating the effects of Impella vs IABP on 30天全因死亡.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy